CENTESSA PHARMACEUTICALS (260) - Total Assets
Based on the latest financial reports, CENTESSA PHARMACEUTICALS (260) holds total assets worth €641.76 Million EUR (≈ $750.29 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CENTESSA PHARMACEUTICALS stock price for real-time trading data and today's change.
CENTESSA PHARMACEUTICALS - Total Assets Trend (2021–2025)
This chart illustrates how CENTESSA PHARMACEUTICALS's total assets have evolved over time, based on quarterly financial data. Also see CENTESSA PHARMACEUTICALS cash flow conversion for how efficiently the company converts equity into cash flow.
CENTESSA PHARMACEUTICALS - Asset Composition Analysis
Current Asset Composition (December 2025)
CENTESSA PHARMACEUTICALS's total assets of €641.76 Million consist of 53.5% current assets and 46.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.9% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how CENTESSA PHARMACEUTICALS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CENTESSA PHARMACEUTICALS current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CENTESSA PHARMACEUTICALS's current assets represent 53.5% of total assets in 2025, a decrease from 99.9% in 2021.
- Cash Position: Cash and equivalents constituted 8.9% of total assets in 2025, down from 94.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
CENTESSA PHARMACEUTICALS Competitors by Total Assets
Key competitors of CENTESSA PHARMACEUTICALS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
CENTESSA PHARMACEUTICALS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.53 | 14.37 | 21.52 |
| Quick Ratio | 9.53 | 14.37 | 21.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €312.11 Million | €323.52 Million | €541.96 Million |
CENTESSA PHARMACEUTICALS - Advanced Valuation Insights
This section examines the relationship between CENTESSA PHARMACEUTICALS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.51 |
| Latest Market Cap to Assets Ratio | 7.79 |
| Asset Growth Rate (YoY) | 19.2% |
| Total Assets | €687.50 Million |
| Market Capitalization | $5.35 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values CENTESSA PHARMACEUTICALS's assets at a significant premium (7.79x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: CENTESSA PHARMACEUTICALS's assets grew by 19.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CENTESSA PHARMACEUTICALS (2021–2025)
The table below shows the annual total assets of CENTESSA PHARMACEUTICALS from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €687.50 Million ≈ $803.75 Million |
+19.19% |
| 2024-12-31 | €576.80 Million ≈ $674.34 Million |
+60.11% |
| 2023-12-31 | €360.25 Million ≈ $421.17 Million |
-18.92% |
| 2022-12-31 | €444.31 Million ≈ $519.44 Million |
-29.43% |
| 2021-12-31 | €629.63 Million ≈ $736.11 Million |
-- |
About CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hyperso… Read more